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Luciferase-based imaging allows a global view of microbial pathogenesis. We applied this
technique to gammaherpesvirus infection by inserting a luciferase expression cassette into the
genome of murine herpesvirus-4 (MuHV-4). The recombinant virus strongly expressed luciferase
in lytically infected cells without significant attenuation. We used it to compare different routes of
virus inoculation. After intranasal infection of anaesthetized mice, luciferase was expressed in the
nose and lungs for 7–10 days and in lymphoid tissue, most consistently the superficial cervical
lymph nodes, for up to 30 days. Gastrointestinal infection was not observed. Intraperitoneal
infection was very different to intranasal, with strong luciferase expression in the liver, kidneys,
intestines, reproductive tract and spleen, but none in the nose or lungs. The nose has not
previously been identified as a site of MuHV-4 infection. After intranasal infection of non-
anaesthetized mice, it was the only site of non-lymphoid luciferase expression. Nevertheless,
lymphoid colonization and persistence were still established, even at low inoculation doses. In
contrast, virus delivered orally was very poorly infectious. Inoculation route therefore had a major
impact on pathogenesis. Low dose intranasal infection without anaesthesia seems most likely to
mimic natural transmission, and may therefore be particularly informative about normal viral gene
functions.
INTRODUCTION
Gammaherpesviruses are highly prevalent and cause
considerable disease. A major challenge in combating this
disease is to understand natural infection, for example how
gammaherpesviruses firstenter theirhosts.Neither Epstein–
Barr virus (EBV) nor Kaposi’s sarcoma-associated herpes-
virus (KSHV) are easy to analyse, because their infections
are largely limited to humans. Gammaherpesviruses that
allow experimental in vivo analysis can therefore tell us a
great deal. Murine herpesvirus-4 (MuHV-4) (Nash et al.,
2001; Stevenson & Efstathiou, 2005) currently provides the
most accessible model. The archetypal MHV-68 strain came
from a bank vole (Myodes glareolus) (Blaskovic et al., 1980).
However, MuHV-4 has also been isolated from yellow-
necked mice (Apodemus flavicollis) (Kozuch et al., 1993),
and closely related viruses have been isolated from a shrew
(Crocidura russula) (Chastel et al., 1994) and from wood
mice (Apodemus sylvaticus) (Blasdell et al., 2003), suggesting
that MuHV-4-like viruses have wide host ranges. Although
MuHV-4 has not been isolated from house mice (Mus
musculus), the natural correlate of inbred laboratory strains,
its benign persistence in laboratory mice contrasts with the
high pathogenicity or marked attenuation generally shown
by herpesviruses in xenogenic hosts (Stevenson et al.,
2002a). There is serological evidence that MuHV-4 (or a
closerelative)naturallyinfectshousemice(Mistrikovaet al.,
2000), and MuHV-4 major histocompatibility complex
(MHC) class I degradation (Boname & Stevenson, 2001;
Lybarger et al., 2003), transporter associated with antigen
processing (TAP) degradation (Boname et al., 2004),
complement inhibition (Kapadia et al., 1999) and chemo-
kine binding (Parry et al., 2000; van Berkel et al., 2000) all
work in laboratory mice. Such immune evasion functions
are typically species-specific, for example MuHV-4 K3
downregulates MHC class I expression poorly in rat cells
(our unpublished data). MuHV-4 infection of laboratory
mice therefore seems to provide a reasonable pathogenesis
model.
Experimental MuHV-4 infection typically employs intra-
nasal virus inoculation under general anaesthesia. This
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006569 G 2009 SGM Printed in Great Britain 21leads to a lytic infection of lung alveolar epithelial cells that
is controlled within 2 weeks (Nash & Sunil-Chandra,
1994). Virus meanwhile seeds to lymphoid tissue and
drives the proliferation of latently infected B cells. This
peaks at 2 weeks post-infection (p.i.) and is controlled by
4 weeks. A predominantly latent infection of memory B
cells (Flano et al., 2002) then persists. In addition to
intranasal infection, MuHV-4 has been given intraperito-
neally (Weck et al., 1996), subcutaneously (Raslova et al.,
2001), intravenously (Sunil-Chandra et al., 1992), orally
(Blaskovic et al., 1984), intracerebrally (Terry et al., 2000)
and by gavage (Peacock & Bost, 2000). Its capacity to infect
many different anatomical sites corresponds to a broad
tropism for different fibroblast and epithelial cell lines
(Gillet et al., 2007a).
All inoculation routes lead to B-cell infection, and latently
infected B cells can in theory transport MuHV-4 from any
one site to any other. It is therefore often assumed that the
different modes of infection are fairly equivalent. However,
the peak of B-cell colonization coincides with a strong
CD8
+ T-cell response (Stevenson et al., 1999a) that limits
lytic spread (Stevenson et al., 1999b), and there is evidence
from EBV that latently infected B cells recirculate mainly
through their site of initial infection (Laichalk et al., 2002).
The exposure of different epithelial and fibroblast popula-
tions to MuHV-4 infection may therefore depend strongly
on inoculation route. Even without a direct comparison, it
is clear that inoculation route can affect experimental
outcomes. For example, intraperitoneal MuHV-4 infection
led to the conclusion that B cells support acute lytic
replication and macrophages support long-term latency
(Weck et al., 1996), whereas after intranasal infection,
macrophage colonization is transient and B cells provide
the long-term latent reservoir (Sunil-Chandra et al., 1992).
A major impetus to establishing a realistic form of
experimental MuHV-4 infection has been the finding that
in vitro and in vivo virus neutralization are quite different
(Gillet et al., 2007b). The implication is that to understand
neutralization, we must also understand host entry. Global
imaging provides one way to compare different infection
routes. Here we imaged MuHV-4 lytic gene expression by
luciferase expression and charge-coupled-device camera
scanning (Hutchens & Luker, 2007). After intranasal virus
inoculation without anaesthesia, luciferase expression was
limited to the nose and superficial cervical lymph nodes
(SCLN), but still established a persistent infection. In
contrast, orally delivered virus was poorly infectious. The
nose therefore seems a likely physiological route of host
entry. Studies of infection by this route may give new
insights into MuHV-4 gene functions.
METHODS
Mice. Female BALB/c mice were infected with MuHV-4 when 6–
12 weeks old. Intranasal infections with anaesthesia were in 30 ml
aliquots, those without were in 5 ml. All experiments conformed to
local animal ethics regulations; those in Cambridge also followed
Home Office Project Licence 80/1992. For luciferase imaging, mice
were injected intraperitoneally with luciferin, anaesthetized with
ketamine/xylazine or isoflurane, then scanned with an IVIS Lumina
(Caliper Life Sciences). In preliminary experiments we used the
manufacturer’s recommended dose of 150 mg luciferin g
21. In later
experiments this was reduced to 2 mg/mouse without noticeably less
signal. Signal intensity was fairly constant between 3 and 10 min after
injection. Mice were routinely imaged after 5 min. For quantitative
comparisons, we used Living Image software (Caliper Life Sciences)
to obtain the maximum radiance (photons per s per cm
2 per
steradian, i.e. photons s
21 cm
22 sr
21) over each region of interest,
relative to a negative control region.
Cells. Baby hamster kidney (BHK-21) cells, NIH-3T3 cells, NIH-
3T3-CRE cells (Stevenson et al., 2002b) and NIH-3T3-TET50 cells
were propagated in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 2 mM glutamine, 100 U penicillin
ml
21, 100 mg streptomycin ml
21 and 10% fetal calf serum. NIH-
3T3-TET50 cells were made by serially transducing NIH-3T3 cells
with three retroviruses: one expressed ORF50 from a promoter with
doxycycline-responsive (TRE) promoter; one expressed constitu-
tively a transcriptional suppressor with doxycycline-inactivated
TRE-binding; and one expressed constitutively a transcriptional
activator with doxycycline-activated TRE-binding. All together
allowed doxycycline-inducible ORF50 expression. The ORF50
coding sequence was amplified by PCR from infected cell cDNA
and cloned into pREV-TRE (Clontech). The TRE-binding tran-
scriptional suppressor was excised from pTET-tTS (Clontech) with
EcoRI/ClaI, the ClaI site was blunted with T4 DNA polymerase and
the fragment was ligated into the EcoRI-blunted XhoIs i t e so f
pMSCV-IRES-PURO. The TRE-binding transcriptional activator
was from pREV-TET-ON (Clontech). Each plasmid was transfected
into 293T cells together with the pEQPAM3 packaging plasmid
(Persons et al., 1998). Retroviruses were collected after 48 and 72 h,
a n da d d e dt oc e l l sw i t h6mgp o l y b r e n em l
21. Triply transduced cells
were selected with puromycin+hygromycin+G418.
Viruses. The luciferase coding sequence plus polyadenylation signal
was removed from pGL4.10 (Promega) by digestion with BglII/SalI
and cloned into the BamHI/SalI sites of pSP73, downstream of a
500 bp MuHV-4 M3 promoter (May et al., 2005a). M3-luciferase-
polyA was then excised with BglII/SalI, blunted with Klenow
fragment DNA polymerase and cloned into the blunted MfeI site
(genomic co-ordinate 77176, GenBank accession no. U97553) of a
BglII MuHV-4 genomic clone (co-ordinates 75338–78717), again in
pSP73. The expression cassette plus genomic flanks was subcloned
into the BamHI site of the pST76K-SR shuttle vector and
recombined into a MuHV-4 bacterial artificial chromosome (BAC;
Adler et al., 2000). An ORF50-deficient derivative was made by
cloning a HincII genomic fragment (co-ordinates 63844–70433)
into the HincII site of pUC9 (New England Biolabs), with the
BamHI site of pUC9 at the 70433 end of the insert. This was cut
with BsmI (67792) and ClaI (69177) to remove most of ORF50 exon
2 (67661–69376), blunted and dephosphorylated with Antarctic
alkaline phosphatase (New England Biolabs). The eGFP coding
sequence from pEGFP-N3 (Clontech) was ligated in place of the
removed fragment. EGFP plus its genomic flanks was then excised
using a genomic KpnI site (66120) and the BamHI site in pUC9,
cloned into the BamHI/KpnI sites of pST76K-SR, and recombined
into the M3-LUC BAC. M3-LUC virus was recovered by transfecting
BAC DNA into BHK-21 cells. For in vivo experiments, its loxP-
flanked BAC/eGFP cassette was removed by passage through NIH-
3T3-CRE cells. Virus stocks were grown in BHK-21 cells (Coleman et
al., 2003). ORF50
2M3-LUC virus was recovered by transfecting BAC
DNA into NIH-3T3-TET50 cells and propagated by treating the cells
with doxycycline.
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on BHK-21 cells (de Lima et al., 2004), or on doxycycline-treated
NIH-3T3-TET50 cells for ORF50
2M3-LUC. Cell monolayers were
incubated with virus (2 h, 37 uC), overlaid with 0.3% carboxy-
methylcellulose, and 4 days later fixed and stained for plaque
counting. Infectious virus in lungs was measured by freeze–thawing
the lungs and homogenizing them in 1 ml complete medium prior to
plaque assay. Latent virus was measured by infectious centre assay (de
Lima et al., 2004): spleen cells were co-cultured with BHK-21 cells,
then fixed and stained for plaque counting after 4 days. Plaque assay
titres of freeze–thawed lymphoid homogenates were always ,1%of
infectious centre assay titres, so the latter essentially measured
reactivable latent virus.
Viral genome quantification. Viral genome loads were measured by
real-time PCR (Gaspar et al., 2008). DNA from organs (50–80 ng) was
used to amplify MuHV-4 genomic co-ordinates 4166–4252 (Rotor Gene
3000; Corbett Research). The PCR products were quantified by
hybridization with a TaqMan probe (genomic co-ordinates 4218–4189)
and converted to genome copies by comparison with a standard curve of
cloned plasmid template amplified in parallel. Cellular DNA was
quantified in parallel by amplifying part of the adenosine phosphoribosyl
transferase gene (forward primer 59-GGGGCAAAACCAAAAAAGGA-39,
reverse primer 59-TGTGTGTGGGGCCTGAGTC-39,p r o b e5 9-TGCCTA
AACACAAGCATCCCTACCTCAA-39).
Southernblotting.ViralDNAwasextractedbyalkalinelysis(Coleman
et al., 2003), digested, electrophoresed and transferred to nylon
membranes (Roche Diagnostics). A [
32P]dCTP-labelled probe
(APBiotech) was generated by random primer extension (DECAprime
II kit; Ambion). Membranes were hybridized with probe (65 uC, 18 h),
washed in 30 mM sodium chloride, 3 mM sodium citrate, 0.1% SDS
solution at 65 uC and exposed to X-ray film.
In vitro luciferase assays. Cells were washed twice in PBS, then
lysed in 1% Triton X-100 (15 min, 4 uC). Cell debris was pelleted
(13000 g, 5 min) and supernatants incubated in 20 mM glycylgly-
cine, 20 mM potassium phosphate buffer (pH 7.8) with 1 mM
dithiothreitol, 10 mM MgSO4, 3 mM EGTA, 2.5 mM ATP and
100 mM luciferin. The light emission of triplicate samples was
detected by luminometry (Hewlett Packard).
ELISA. MuHV-4 virions were recovered from infected cell super-
natants by ultracentrifugation, disrupted with 0.05% Triton X-100 in
50 mM sodium carbonate buffer (pH 8.5), and coated onto MaxiSorp
ELISA plates (Nunc). The plates were washed three times in PBS
containing 0.1% Tween 20, blocked with 2% BSA in PBS 0.1%
Tween 20, then incubated with threefold serum dilutions from
MuHV-4-exposed mice (1 h, 23 uC). The plates were then washed
four times in PBS 0.1% Tween 20, incubated (1 h, 23 uC) with
alkaline phosphatase-conjugated goat anti-mouse IgG-Fc pAb
(Sigma), washed five times, and developed with nitrophenylpho-
sphate (Sigma). Absorbance was measured at 405 nm (Bio-Rad).
RESULTS
Generation and in vitro analysis of MuHV-4
expressing luciferase
An ideal luciferase reporter would mark both lytically and
latently infected cells. However, high level latent gene
expression is probably incompatible with normal host
colonization for a gammaherpesvirus: most EBV-infected
cells express no latency genes at all (Thorley-Lawson,
2001); both EBV and MuHV-4 limit antigen presentation
from their episome maintenance proteins by low turnover
(Yin et al., 2003; Bennett et al., 2005); and bypassing this
evasion severely attenuates MuHV-4 latency (Bennett et al.,
2005). Autonomous promoters such as that of the human
cytomegalovirus (HCMV) IE1 gene (Rosa et al., 2007;
Smith et al., 2007) may therefore expose latently infected
cells to unphysiological CD8
+ T-cell recognition. This
would explain why HCMV IE1-driven reporter gene
expression is associated with marked in vivo MuHV-4
attenuation (Adler et al., 2001).
We therefore aimed for lytic reporter gene expression, using
as a promoter an ectopic copy of the 500 bp upstream of the
MuHV-4 M3, an abundant early/late lytic gene (van Berkel et
al., 1999). In situ detection of M3 mRNA in infected
lymphoid tissue (Simas et al., 1999) and a latency
establishment deficit of MuHV-4 M3 mutants (Bridgeman
et al., 2001) suggest that M3 might also be transcribed in
latency.However,otherearlylytictranscriptsaredetectablein
spleens (Marques et al., 2003) – B cellseven drive a substantial
lytic antigen-specific CD8
+ T-cell response (Stevenson et al.,
1999a) – and the latency deficit of M3 mutants may simply
reflect that lytically infected cells no longer secrete M3 to
provide bystander protection for their latently infected
neighbours (Rice et al., 2002; Stevenson, 2004).
The luciferase expression cassette was inserted between the
polyadenylationsignalsofORFs57 and58(Fig.1a). Southern
blotting (Fig. 1b) confirmed the predicted structures of
recombinant viral genomes. Infected cells showed strong
luciferase expression (Fig. 1c). M3-LUC viruses showed no in
vitro lytic replication defect (Fig. 1d). Since ORF57 is essential
for lytic replication (Song et al., 2005) and ORF58 contributes
to inter-cellular viral spread (May et al., 2005b), luciferase
expression appeared not to compromise the functions of
neighbouring genes. Gp48 expression, which is ORF58-
dependent, was also normal (data not shown).
We tested whether M3-LUC luciferase expression depended
on the ORF50 lytic transactivator by generating an ORF50-
deficient derivative (Fig. 1e). This was propagated in
complementing NIH-3T3-TRE50 cells and then tested for
luciferase expression in non-complementing BHK-21 cells. At
0.1 p.f.u. cell
21, ORF50 disruption reduced the luciferase
signal by 98–99%. At 1 p.f.u. cell
21 the reduction was 80%.
Inhibiting viral DNA replication with phosphonoacetic acid
had no effect on luciferase expression (data not shown). Thus,
luciferase expression corresponded mainly to early lytic gene
expression, with some additional ORF50-independent expres-
sion at high multiplicity infection. In vivo cells may differ from
transformed cell lines in viral transcription, but it seemed
unlikely that luciferase expression would reveal latent
infection.Weconsidered it to mark early lyticgene expression.
In vivo analysis of MuHV-4 expressing luciferase
We have previously shown that M3 promoter-driven
ovalbumin or eGFP expression has a minimal effect on
Imaging MuHV-4 in vivo
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viruses similarly showed normal replication after intranasal
inoculation (Fig. 2a). We selected M3-LUC2.1 for further
analysis. We infected anaesthetized mice intranasally, then
monitored luciferase expression by luciferin injection and
charge-coupled-device camera scanning (Fig. 2b). In
preliminary experiments, removing the fur from mice
prior to imaging had little effect on the signal obtained.
Therefore in subsequent experiments no fur was removed.
At the peak of lytic replication (5–7 days p.i.), a strong
signal was visible in the thorax and the nose. At the peak of
latency amplification (13–14 days p.i.), luciferase signals
were weak or undetectable in the thorax and nose, but
strong in the neck. Some mice also showed a weaker
abdominal signal.
Ex vivo imaging of dissected organs (Fig. 3) established the
sources of the live images. The thoracic signal came from
the lungs; the abdominal signal came from the spleen; and
the neck signal came from the SCLN, particularly the most
rostral node that lies alongside the salivary glands. The
mediastinal (subthymic) and deep cervical LN showed
weaker signals. Despite strong signals from nose and lungs,
we saw no signal from the intervening trachea or main
bronchi. Although MuHV-4 has been reported to infect
mice after inoculation into the stomach (Peacock & Bost,
2000), and at least some of a 30 ml intranasal inoculum is
likely to be swallowed, we saw no sign of intestinal
infection. A signal was occasionally observed (10–20% of
mice) in the liver at day 7 (Fig. 3) and in abdominal LN at
day 10–14 (data not shown). This could have reflected
Fig. 1. Generation of MuHV-4 expressing luciferase. (a) A 2 kb luciferase-polyA cassette was placed downstream of a 500 bp
M3 promoter, in a MfeI restriction site between ORFs 57 and 58. Relevant restrictions sites are shown. (b) Viral DNA was
digested with EcoRI or HindIII and probed with the 75338–78717 BglII clone shown in (a). The luciferase expression cassette
changes a 14.9 kb EcoRI band to 5.5 kb+12.0 kb, and a 14.5 kb HindIII band to 6.8 kb+10.1 kb. M3-LUC1.6 and M3-
LUC2.1 are independently generated recombinant viruses. (c) BHK-21 cells were left uninfected or infected overnight (1 p.f.u.
cell
”1), then lysed and assayed for luciferase expression. Each bar shows the mean±SD of triplicate cultures. (d) BHK-21 cells
were infected with wild-type or M3-LUC MuHV-4 (0.01 p.f.u. cell
”1, 2 h), washed with PBS to remove unbound virions, then
incubated at 37 6C. The infectious virus in each culture was measured by plaque assay. (e) BHK-21 cells were infected with
wild-type MuHV-4, the M3-LUC2.1 recombinant or its ORF50
” derivative. Luciferase expression was assayed 18 h later by
luminometry. Each bar shows mean±SD of five replicate infections. The ORF50
” cultures contained no replication-competent
virus by plaque assay.
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contiguous spread from the lungs and diaphragm or
systemic virus spread via B cells. Other abdominal organs,
such as the kidneys and reproductive tract, were con-
sistently negative.
Quantification of luciferase signals
Luciferase signals were quantified as the maximum
radiance (photons s
21 cm
22 sr
21) over a region of
interest – typically one dissected organ. Fig. 4 shows a
time-course after intranasal infection. Occasional mice
showed no signal even at peak average time points.
Tracking individual mice showed that none remained
uninfected. Rather the kinetics of luciferase expression
varied; total signals over the whole time-course were
similar. This possibly reflecte dv a r i a t i o ni ni n o c u l u md o s e
t ot h el u n g :s o m ev i r u sm a yh a v eb e e nt r a p p e di nn a s a l
sinuses or coughed up after recovery from anaesthesia.
SCLN signals were the most long-lived, sometimes
persisting even at day 25 p.i. But generally all sites were
negative by day 30.
Several caveats apply to live imaging. Overlying tissues
clearly reduced light transmission, as neck signals were
evident ventrally but not dorsally, and the dissected organs
signals were stronger than live images. This limits the
interpretation of fine quantitative differences. Mediastinal
LN and deep cervical LN signals were only evident after
dissection because they were obscured by those of the lungs
and SCLN. Very strong signals sometimes gave secondary
reflections. For example, in the day 14 ventral view (Fig.
2b), the neck signal is reflecting off the incisors: after
dissection, no mouth signal was observed. However, there
was generally a good correlation between live images and
dissected organ signals.
Since luciferase expression corresponded to early lytic gene
expression, a lack of signal did not necessarily imply a lack
of infection: tightly maintained viral latency might be
missed. The lytic antigen-specific CD8
+ T-cell responses
generated by 7–10 days p.i. (Stevenson & Doherty, 1998)
Fig. 3. Luciferase signals from isolated organs after intranasal
MuHV-4 infection. Mice equivalent to those in Fig. 2(b) were
dissected and their organs imaged ex vivo. Each image is
representative of data from at least five mice, and shows either a
standard photograph (Photo) or that photograph overlaid with the
luciferase signal (Photo+LUC). The colour scheme for relative
signal intensity is as for Fig. 2.
Fig. 2. In vivo infection by luciferase-expressing MuHV-4. (a) M3-
LUC1.6 and M3-LUC2.1 were compared with wild-type MuHV-4
for their capacity to colonize mice after intranasal infection. Lytic
replication was tested by plaque assay of lungs after 5 days.
Latency establishment was tested by infectious centre assay of
spleens after 13 days. Each point shows the titre of one mouse.
There was no significant difference between each virus. (b) Mice
were infected intranasally (10
4 p.f.u.) with M3-LUC2.1 MuHV-4
under general anaesthesia, and then injected with luciferin and
imaged every 3–4 days. Images show a representative mouse at
day 7 and 14 p.i. The signal in the mouth was atypical and probably
corresponds to the strong neck signal reflecting off the incisors.
The scale bar shows photons s
”1 cm
”2 sr
”1.
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Nevertheless, luciferase signals appeared to match quite
well the results of other assays (Sunil-Chandra et al., 1992):
an acute lytic infection in the lung (day 4–10) progressed to
a subacute infection of lymphoid tissue (day 10–25), and
both were largely resolved by day 30. Although MuHV-4
does not show significant productive infection in lymphoid
tissue after intranasal inoculation (Nash & Sunil-Chandra,
1994), luciferase signals here were entirely consistent with
evidence of early lytic gene expression (Stevenson et al.,
1999a; Liu et al., 1999; Marques et al., 2003). Thus, early
lytic luciferase expression revealed both productive lytic
replication and acute lymphoid colonization.
Intraperitoneal infection
Many MuHV-4 pathogenesis studies have used intraper-
itoneal infection rather than intranasal (Speck & Virgin,
1999). Understanding the relationship between these
infections is therefore important for integrating existing
pathogenesis data into a coherent whole. Luciferase
expression patterns after intraperitoneal or intranasal
M3-LUC inoculations were markedly different (Fig. 5a).
At day 4 after intraperitoneal inoculation, there was a
strong signal from the abdominal cavity and none from the
nose or lungs. At the same time after intranasal
inoculation, there was a strong signal from the lungs and
none from the abdomen. By 10 days after intraperitoneal
inoculation, there was still no signal from the lungs. The
abdominal signal had decreased, and the only spread was to
the mediastinal LN, which receive lymphatic drainage from
the peritoneal cavity; the strong SCLN signal associated
with intranasal infection remained weak or absent.
Ex vivo imaging (Fig. 5b) showed that the abdominal signal
of intraperitoneal infection had many sources, including the
liver, spleen, kidneys and reproductive tract. The gut was
also patchily positive, presumably reflecting serosal infec-
tion. Therefore, although MuHV-4 reached lymphoid tissue
by either route, the distributions of lytic infection were
almostmutuallyexclusive; in neither case didinfected B cells
appear to seed major new non-lymphoid sites of lytic gene
expression. Even the spleen signals differed: intraperitoneal
infection showed strong luciferase expression early on,
consistent with productive infection (Weck et al., 1996),
while intranasal infection showed later, weaker expression,
consistent with a predominantly latent infection. These data
explained why intraperitoneal and intranasal infections have
given such different phenotypes, for example with M11
knockouts (Gangappa et al., 2002; de Lima et al., 2005).
Different infection doses
We next tested different inoculation doses via the intranasal
route with general anaesthesia (Fig. 6). High dose infection
(10
5 p.f.u.) gave a luciferase signal in the lung that peaked at
4–7 days. After low dose infection (10
2 p.f.u.) the signal
peaked at 8–11 days and was generally less extensive. Both
infections led to lymphoid colonization. Thus, beyond more
virus giving more extensive early lytic replication, there was
little difference between low and high doses, consistent with
infectivity assays (Tibbetts et al., 2003). Luciferase signals in
the nose were uncommon after low dose infection,
presumably because all the infectious particles ended up in
the lungs. SCLN signals were also weak, implying that this
site is colonized principally via the upper respiratory tract.
Intranasal infection without anaesthesia
The prominent luciferase signals in noses after intranasal
inoculation suggested that host entry might occur via the
Fig. 4. Quantification of luciferase signals from isolated organs
after intranasal MuHV-4 infection. Mice were infected intranasally
(10
4 p.f.u.) with M3-LUC. At each time point, at least five mice per
group were dissected for ex vivo organ imaging. Each point shows
the maximum radiance value for one mouse. The horizontal dashed
lines mark an arbitrary sensitivity threshold, chosen to minimize the
chance of artefactual signals such as secondary light reflections.
Fig. 5 Comparison of intranasal and intraperitoneal MuHV-4 infections. (a) Mice were inoculated intranasally or
intraperitoneally with 10
4 p.f.u. of M3-LUC, then monitored for luciferase expression. Representative pairs of mice are
shown. (b) Mice were dissected at 4 or 10 days after intraperitoneal virus inoculation to identify the source of the live imaging
signals. The colour scheme for relative signal intensity is as for Fig. 2.
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mostly been studied to date. We tested this by intranasal
infection without anaesthesia (Fig. 7). As before, the
anaesthetized controls showed strong luciferase signals in
lungs and less consistent signals in the nose (Fig. 7a, b).
Infection then spread to the SCLN and spleen. Non-
anaesthetized mice given the same virus dose showed a
strong signal in the nose and none in the lungs. Thus,
infection did not reach the lungs without anaesthesia. Non-
anaesthetized mice also showed no luciferase signal in the
spleen. However, their SCLN signals were at least as strong
as those of anaesthetized mice. The lack of spleen signal
presumably reflected that it was colonized relatively late in
infection, when lytic antigen-specific CD8
+ T-cell
responses were strong. Real-time PCR quantification of
viral genomes (Fig. 7c) established that virus delivered to
the nose still established normal persistence in both the
SCLN and spleen.
Oral infection
We also tested oral infection (Fig. 8). A 10
4 p.f.u. inoculum
with general anaesthesia gave no luciferase signal in 3/5
mice. What mice were infected showed the typical lung-
dominated pattern of intranasal infection (Fig. 8a),
suggesting aspiration of the oral inoculum. A 10
6 p.f.u.
inoculum without anaesthesia gave luciferase signals in 5/8
mice. This time, the infected mice had the typical pattern
of nose infection (Fig. 8b), suggesting that here some of the
oral inoculum reached the nose. Thus, there was no
evidence of host entry by the oral route: normal infection
was established if virions reached the nose or lung, but
there was no infection if they did not.
Lower dose infections without anaesthesia – reducing the
chance of inadvertent respiratory tract contamination –
gave no luciferase signal (0/10 mice for 10
3 p.f.u.; 0/24
mice for 50 p.f.u.), even when we imaged dissected organs.
In contrast, a 10 p.f.u. intranasal inoculum without
anaesthesia gave strong luciferase signals in 12/12 mice. A
lack of infection by 50 p.f.u. of oral virus was confirmed by
ELISA for virus-specific serum IgG at 1 month post-
exposure (Fig. 8c). PCR of spleen cell DNA for viral
genomes at 15 days after oral inoculation was also
completely negative in 6/6 mice (,5 viral genome copies
per 80 ng DNA). Thus in adult mice, oral MuHV-4 was
poorly infectious.
DISCUSSION
How do herpesviruses enter their hosts? We compared
different modes of experimental MuHV-4 infection,
aiming to establish a plausible correlate of natural
transmission for adult mice. For an anatomically complete
view, we monitored infection by luciferase expression from
the viral genome. Analysis of the standard intranasal
infection model validated this approach. Thus, strong
luciferase expression in the lung, weaker expression in
lymphoid tissue, then quiescence, matched the consensus
picture from other assays of productive viral replication in
the lung, latency amplification with some lytic gene
expression in lymphoid tissue, then immune control.
Different modes of virus inoculation gave markedly
different patterns of luciferase expression. Intranasal
inoculation under general anaesthesia gave strong expres-
sion in the nose and lungs and weaker expression in
lymphoid tissue; intraperitoneal inoculation gave strong
expression in multiple abdominal organs, including the
spleen, and none in the respiratory tract; intranasal
Fig. 6. High dose and low dose intranasal infections. Mice were
infected intranasally with M3-LUC (10
2 or 10
5 p.f.u.) under
general anaesthesia, then live-imaged for luciferase expression
every 3–5 days. Each point corresponds to one mouse. The
horizontal dashed lines mark an arbitrary sensitivity threshold.
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4 p.f.u.), either
awake or while anaesthetized, then imaged for luciferase expression every 3–5 days. Each point corresponds to one mouse.
The horizontal dashed lines mark an arbitrary sensitivity threshold. (b) Representative images from the data summarized in (a).
(c) At 1 month p.i., mice were analysed for viral genome loads in the spleen and SCLN by real-time PCR. The top panel shows
the cellular control (APRT), the middle panel the MuHV-4 M2 gene, and the bottom panel the M2 load normalized by APRT.
Each point corresponds to one mouse. There was no statistically significant difference between mice given anaesthesia (Inf.
lung) or not (Inf. nose).
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nose and draining lymphoid tissue; and oral inoculation
gave no expression at all. Normal transmission is
presumably mucosal. The nose – but not the lung – is
therefore a likely point of normal host entry.
The poor infectivity of oral MuHV-4 was surprising, as
human gammaherpesviruses are thought to transmit orally
via saliva. MuHV-4 may use nasal entry because noses
feature more prominently in murine social life. The
nasopharynx may also be important for human gamma-
herpesvirus transmission: there is little evidence for a
specifically oral EBV or KSHV entry route, and EBV
infection notably predisposes to nasopharyngeal carcin-
oma.
The limited lytic spread of MuHV-4 from the nose might
be seen as suboptimal for host colonization. However,
gammaherpesvirus epidemiology indicates that transmis-
sion depends more on long-term virus shedding than
primary lytic infection, and this correlates with the latent
load (Yao et al., 1985). MuHV-4 latency is relatively
independent of the extent of primary lytic infection
(Stevenson et al., 1999c; Coleman et al., 2003). It depends
much more on latency-associated lymphoproliferation
(May et al., 2004). Extensive primary lytic spread might
even be counter-productive by providing a powerful
immune stimulus and by predisposing the host to disease.
Thus, gammaherpesviruses may have evolved to infect their
hosts without extensive lytic spread.
The apparent failure of intranasal MuHV-4 to infect the
oropharynx or trachea, and of oral MuHV-4 to infect
anywhere, suggest that incoming virions cross epithelia by
specialized routes. Although MuHV-4 virions readily infect
most epithelial cells in vitro, their strong dependence on
heparan sulphate for cell binding (Gillet et al., 2008) raises
questions about epithelial infection in vivo, as here heparan
sulfate is predominantly basolateral rather than apical
(Hayashi et al., 1987). In vitro epithelial infection may
correspond more to host exit, when virions would emerge
from B cells to infect basolaterally. Notably, MuHV-4
infects confluent, polarized in vitro epithelial monolayers
much less well than subconfluent monolayers (our
unpublished data).
An important task now is to identify the cell types targeted
in the nose. This is not necessarily straightforward: high
dose inocula may reach non-physiological sites, low dose
inocula are inherently hard to track, and once there is viral
replication, histology may fail to distinguish host entry
from exit. Entry via the nose may be qualitatively different
to that via the lungs or the peritoneal cavity. The latter
both contain abundant macrophage populations without
an epithelial barrier, and peritoneal macrophages at least
are quite readily infected (Rosa et al., 2007). A related
question is how incoming virions reach B cells. This may
occur submucosally or in lymph nodes. The strong
luciferase signals in SCLN following nasal infection argued
for a significant lymphatic transport of infectious virions to
this site. One precedent for such transport is normal
immune priming (Belz et al., 2007). A role for dendritic
cells in B-cell infection would therefore not be surprising.
The present study provides a basis for further understand-
ing by identifying the nose as an entry point and the SCLN
as the major associated lymphoid target.
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